Calithera Biosciences (CALA) – Company Press Releases
-
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
-
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
-
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
-
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
-
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
-
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
-
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
-
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
-
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
-
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
-
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
-
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
-
Calithera to Present at the H.C. Wainwright Global Investment Conference
-
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
-
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
-
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
-
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
-
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
-
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022
-
Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting
-
Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
-
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
-
Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
-
Calithera to Present at the 2021 Jefferies London Healthcare Conference
-
Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
-
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
-
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
-
Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
-
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021
-
Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021
-
Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals
-
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer
-
Calithera Biosciences to Participate in Two Upcoming Investor Conferences
-
Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
-
Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
-
Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting
-
Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference
-
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)
-
Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
-
Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
-
Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
-
Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting
-
Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights
-
UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021
-
Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021
-
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference
-
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
-
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium
Back to CALA Stock Lookup
